Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer

The primary objective of this study is to assess the feasibility of randomizing breast cancer patients to quantitative ultrasound to guide adaptive Neoadjuvant Chemotherapy as compared to standard clinical monitoring and therapy. The Investigators have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo. The method can detect different forms of cell death and has been demonstrated to be sensitive to apoptotic, necrotic and mitotic cell death. By de

Trial Details

NCT ID
NCT04050228
Phase
NA
Sponsor
Sunnybrook Health Sciences Centre
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Quantitative ultrasound to guide adaptive chemotherapy
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Women ≥ 18 years of age
  • Diagnosis of breast cancer with a primary tumour \>2cm in size
  • With conditions meeting criteria for chemotherapy administration
  • Normal hematological blood counts (hemoglobin ≥ 100 g/l, platelet count ≥ 100 x 109, absolute neutrophil count ≥ 2.0 x109 cells per L)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →